HSBC reissued their hold rating on shares of Novo Nordisk A/S (NYSE:NVO) in a report issued on Thursday.

Several other research firms also recently commented on NVO. Deutsche Bank AG raised shares of Novo Nordisk A/S from a hold rating to a buy rating in a report on Monday, September 12th. Morgan Stanley downgraded shares of Novo Nordisk A/S from an overweight rating to an equal weight rating in a report on Thursday, September 1st. Bank of America Corp. downgraded shares of Novo Nordisk A/S from a buy rating to a neutral rating in a report on Monday, August 8th. Jefferies Group reaffirmed a hold rating on shares of Novo Nordisk A/S in a report on Wednesday, September 14th. Finally, Goldman Sachs Group Inc. downgraded shares of Novo Nordisk A/S from a conviction-buy rating to a buy rating in a report on Tuesday, June 28th. Seven research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Novo Nordisk A/S has a consensus rating of Buy and a consensus price target of $61.33.

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) traded up 0.1087% during midday trading on Thursday, hitting $39.7131. 1,758,411 shares of the stock were exchanged. Novo Nordisk A/S has a 1-year low of $39.03 and a 1-year high of $59.00. The company has a market capitalization of $100.72 billion, a P/E ratio of 18.7769 and a beta of 0.73. The company’s 50 day moving average is $44.21 and its 200 day moving average is $51.52.

Several hedge funds and other institutional investors have recently bought and sold shares of NVO. Advisory Services Network LLC raised its stake in shares of Novo Nordisk A/S by 28.8% in the second quarter. Advisory Services Network LLC now owns 2,238 shares of the company’s stock valued at $120,000 after buying an additional 500 shares in the last quarter. J.Safra Asset Management Corp purchased a new stake in shares of Novo Nordisk A/S during the second quarter valued at about $127,000. Ranger International Management LP raised its stake in shares of Novo Nordisk A/S by 49.1% in the second quarter. Ranger International Management LP now owns 2,430 shares of the company’s stock valued at $131,000 after buying an additional 800 shares in the last quarter. Cribstone Capital Management LLC purchased a new stake in shares of Novo Nordisk A/S during the second quarter valued at about $159,000. Finally, Tower Research Capital LLC TRC raised its stake in shares of Novo Nordisk A/S by 2,998.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,098 shares of the company’s stock valued at $167,000 after buying an additional 2,998 shares in the last quarter. Institutional investors own 7.54% of the company’s stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

5 Day Chart for NYSE:NVO

Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.